Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure N.V. reports company news on its gene therapy pipeline, regulatory interactions, clinical data, operating results, and capital structure. The company develops genetic medicines for severe diseases, with disclosed programs including AMT-130 for Huntington’s disease, AMT-260 for refractory mesial temporal lobe epilepsy, AMT-191 for Fabry disease, ALS programs, and an approved gene therapy for hemophilia B.
Recurring updates cover FDA and MHRA discussions, clinical-trial observations, exploratory efficacy and safety data, quarterly and annual financial results, debt financing arrangements, corporate presentations, and governance or shareholder matters tied to its Nasdaq-listed public-company status.
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the first therapy for Huntington’s disease to receive RMAT designation, facilitating closer collaboration with the FDA and potentially expediting its development and approval process. This decision underscores AMT-130's potential to address the unmet medical needs of Huntington’s disease patients.
uniQure plans to present updated interim data from ongoing Phase I/II studies in mid-2024, including follow-up results on 29 treated patients, 21 of whom will have data spanning at least two years.
uniQure N.V. reported its first quarter 2024 financial results and recent progress, focusing on advancing AMT-130 for Huntington's disease and initiating new Phase I/II trials for Fabry disease, ALS, and MTLE. The company is on track to interact with the FDA in Q2 2024 and reduce expenses to increase shareholder value. Financially, uniQure's revenues increased to $8.5 million, with a cash position of $555.7 million as of March 31, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.